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Abstract
Cell adhesion molecules and downstream growth factor-dependent signaling are critical for brain development and
synaptic plasticity, and they have been linked to cognitive function in adult animals. We have previously developed a
mimetic peptide (FGL) from the neural cell adhesion molecule (NCAM) that enhances spatial learning and memory in rats.
We have now investigated the cellular and molecular basis of this cognitive enhancement, using biochemical,
morphological, electrophysiological, and behavioral analyses. We have found that FGL triggers a long-lasting enhancement
of synaptic transmission in hippocampal CA1 neurons. This effect is mediated by a facilitated synaptic delivery of AMPA
receptors, which is accompanied by enhanced NMDA receptor-dependent long-term potentiation (LTP). Both LTP and
cognitive enhancement are mediated by an initial PKC activation, which is followed by persistent CaMKII activation. These
results provide a mechanistic link between facilitation of AMPA receptor synaptic delivery and improved hippocampal-
dependent learning, induced by a pharmacological cognitive enhancer.
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Introduction
Activity-dependent synaptic changes, generally termed synaptic
plasticity, underlie multiple forms of cognitive function, such as
learning and memory [1]. Strong interest has accrued in
understanding the molecular and cellular mechanisms underlying
these changes. Additionally, it is believed that targeted manipu-
lation of these mechanisms may help facilitate or stabilize synaptic
plasticity events, with the aim of potentially improving cognitive
function under pathological, or even physiological, conditions.
Multiple genetic manipulations in animal models have been
shown to produce cognitive enhancement, defined as improved
performance in learning and memory behavioral tasks (see, for
example, [2]). In the vast majority of cases, cognitive-enhancing
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synaptic plasticity (reviewed in [3]), thus reinforcing the interpre-
tation of synaptic plasticity as a cellular substrate for learning and
memory. Nevertheless, the particular mechanism that links
changes in synaptic plasticity with enhanced cognitive function is
poorly defined. Additionally, for therapeutic purposes, there is
great interest in developing pharmacological approaches, rather
than genetic manipulations, that effectively modulate synaptic
plasticity pathways in a well-defined manner.
Cell adhesion molecules are well-known effectors of neuronal
development and structural plasticity [4]. Some of them have also
been linked to synaptic plasticity, learning, and memory [5],
particularly via their interaction with growth factor-mediated
signaling [6]. From this point of view, cell adhesion molecules are
being considered as potential therapeutic targets for the develop-
ment of pharmacological cognitive enhancers. This is the case of
neural cell adhesion molecule (NCAM) [5]. NCAM activity is
essential for both early synaptogenesis and synaptic maturation
[4], and it influences the strength of excitatory synapses in an
activity-dependent manner [7]. NCAM is a member of the
immunoglobulin (Ig) superfamily, containing five N-terminal Ig
modules followed by two fibronectin type III (F3) modules. NCAM
is involved in homophilic and heterophilic interactions, as well as
in the activation of various signal transduction pathways [8].
Importantly, some of the functions of NCAM in cell remodeling
and growth are mediated by fibroblast growth factor receptors
(FGFRs). In fact, NCAM interacts with extracellular domains of
FGFR to modulate FGFR-dependent intracellular signaling [9].
Based on the functional interplay between NCAM and FGFR, we
engineered a synthetic NCAM mimetic peptide, termed FGLoop
(FGL), that encompasses the interaction domain of NCAM with
FGFR: F and G b-strands and the interconnecting loop of the
second F3 module of NCAM (red ribbon in Figure 1A). We
previously showed that FGL elicits FGFR-mediated signaling [10]
and induces neuritogenesis and survival in neuronal cultures [11].
Most importantly, we found that in vivo administration of FGL
enhances spatial and social memory retention in rats [12,13]. FGL
has also been shown to prevent cognitive impairment induced by
stress [14,15] and oligomeric b-amyloid [16], and have antide-
pressant-like effects in rats [17]. Therefore, FGL appears to act as
a bona fide cognitive enhancer, possibly by engaging NCAM-
FGFR-related signaling. However, the synaptic mechanisms by
which this cognitive enhancement is produced remain unknown.
Some of the signaling pathways recruited by FGFR activation
[18] cross-talk with molecular mechanisms associated with
synaptic plasticity, particularly long-term potentiation (LTP).
LTP is one of the best characterized forms of synaptic plasticity
in the hippocampus and is considered to be a cellular correlate for
information storage in the brain during learning and memory
processes [1]. A major contributor to synaptic potentiation during
LTP is the incorporation of new AMPA-type glutamate receptors
(AMPARs) into excitatory synapses via activity-dependent traf-
ficking [19]. Multiple signal transduction pathways have been
shown to regulate AMPAR incorporation into synapses during
LTP, most notably the pathways controlled by Ca
2+/calmodulin-
dependent protein kinase II (CaMKII) [20], mitogen-activated
protein kinase (MAPK) [21], protein kinase C (PKC) [22], and
phosphoinositide-3-kinase (PI3K) [23,24]. These last three path-
ways (MAPK, PKC, and PI3K) are engaged during FGFR-
dependent signaling [18], and therefore, they are attractive
candidates to mediate FGL effects on cognitive function.
The present study uncovers specific synaptic mechanisms and
signaling pathways responsible for the cognitive enhancement
induced by the NCAM-FGFR agonist FGL. In particular, we
show here that FGL enhances LTP in hippocampal slices, and it
does so by facilitating AMPAR delivery at synapses upon
activation of NMDA receptors (NMDARs). These effects are
specifically mediated by PKC activation. Furthermore, behavioral
testing revealed that this PKC-dependent mechanism mediates the
enhanced cognition induced by FGL. Therefore, these results
delineate the intracellular signaling and molecular mechanisms
that lead to enhanced synaptic plasticity and improved learning
and memory caused by a pharmacological cognitive enhancer. In
this manner, we have established a mechanistic link between
facilitation of AMPAR synaptic delivery and enhanced cognition.
Results
FGL Activates FGFR-Dependent Signaling in vivo and
Acts as a Cognitive Enhancer
To start characterizing the signaling pathways that mediate the
cognitive actions of FGL, we tested the ability of FGL to activate
FGFR-dependent signaling in vitroand invivo. We found that FGL
dose-dependently induces FGFR1 phosphorylation in Trex293 cells
transfected with human FGFR1 (Figure 1B). Moreover, FGL
triggers FGFR1 phosphorylation in vivo in the hippocampus after
subcutaneous injection (Figure 1C, black columns) (we have
previously shown that FGL crosses the blood-brain barrier [13]).
As a control, FGL did not induce phosphorylation of TrkB
(Figure 1C, gray columns), the receptor of brain-derived neuro-
trophic factor (BDNF), which is a potent modulator of activity-
dependent synaptic plasticity and shares some signaling pathways
with FGFR [25]. Downstream from FGFR phosphorylation, we
found in transfected Trex293 cells that FGL triggers the
phosphorylation of PLCc (phospholipase C-c) and Shc (Src
homologous and collagen) (Figure 1D and E), but not FRS2 (FGFR
substrate 2) (Figure 1F, black columns), in contrast to FGF1
(Figure 1F, gray columns). Thus, FGL activates a subset of the
signaling pathways triggered by FGF.
After determining that FGL activates FGFR in vivo and in vitro,
we evaluated its cognitive actions. FGL (6.6 mg/kg) or control
vehicle (0.9% NaCl) were injected subcutaneously 5 and 2 d
Author Summary
The human brain contains trillions of neuronal connec-
tions, called synapses, whose pattern of activity controls all
our cognitive functions. These synaptic connections are
dynamic and constantly changing in their strength and
properties, and this process of synaptic plasticity is
essential for learning and memory. Alterations in synaptic
plasticity mechanisms are thought to be responsible for
multiple cognitive deficits, such as autism, Alzheimer’s
disease, and several forms of mental retardation. In this
study, we show that synapses can be made more plastic
using a small protein fragment (peptide) derived from a
neuronal protein involved in cell-to-cell communication.
This peptide (FGL) initiates a cascade of events inside the
neuron that results in the facilitation of synaptic plasticity.
Specifically, we find that FGL triggers delivery of a specific
type of glutamate receptor (AMPA receptors) to synapses
in a region of the brain called the hippocampus, which is
known to be involved in multiple forms of learning and
memory. Importantly, when this peptide was administered
to rats, their ability to learn and retain spatial information
was enhanced. Therefore, this work demonstrates that
cognitive function can be improved pharmacologically in
adult animals by enhancing the plasticity of synaptic
connections in the brain.
AMPA Receptors and Enhanced Cognition
PLoS Biology | www.plosbiology.org 2 February 2012 | Volume 10 | Issue 2 | e1001262Figure 1. FGL triggers hippocampal FGFR1 phosphorylation in vitro and in vivo. (A) Cartoon structure of the double fibronectin module
(FN1+FN2) of human NCAM (Protein Data Bank number 2VKW). The FGL sequence is shown in red with the two glutamine residues critical for the
binding to the FGF-receptor highlighted in magenta. (B) Top: Representative immunoblot showing the in vitro phosphorylation of FGFR1 after
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find a submerged platform in the Morris water maze (see Text S1).
Spatial training was performed with the experimenter blind to the
treatment of each rat. As shown in Figure 2A, FGL-treated rats
outperformed their age-matched controls in this spatial learning
task during the 2 d of training (reflected by significantly shorter
distances swam to find the hidden platform during the training
sessions: F1,18=8.445, p=0.004). This was particularly evident for
all tested animals when comparing individual performance during
the last trial of each training day (Figure 2B). No significant
differences were found in swimming speed between groups
(unpublished data), suggesting that FGL does not have peripheral
effects.
Therefore, we conclude that FGL triggers FGFR-dependent
signaling in the hippocampus in vivo and improves hippocampal-
dependent learning when injected peripherally.
FGL Does Not Alter the Morphology of Dendritic Spines
and Synapses
Most glutamatergic excitatory axons establish synapses with
dendritic spines of pyramidal neurons, and changes in their density
and/or shape are involved in plastic modifications associated with
LTP between CA3 and CA1 pyramidal neurons [26]. Addition-
ally, most CA1 pyramidal neurons express FGFR1 [27] and have
been strongly implicated in spatial navigation and memory [28].
Thus, as a first step to evaluate the cellular substrate of FGL-
induced enhanced cognition, we examined whether dendritic
spines in CA1 stratum radiatum are affected by FGL administra-
tion. To this end, animals were treated with FGL as described
above, and 2 d after the second FGL injection (when cognition
enhancement was observed), the animals were perfused with
fixative, hippocampal sections were prepared, and CA1 neurons
were injected with Lucifer Yellow for analysis of dendritic spine
density and morphology (Figure 3A–B). These analyses were
performed by experimenters blind to the treatment of the animals.
We found no significant differences in spine density (Figure 3C–E),
spine head volume (Figure 3F–J), or neck length (Figure S1)
between FGL- and vehicle-treated animals. Furthermore, sections
adjacent to those used for the intracellular injections were
examined at the electron microscope level. As shown in
Figure 3K–M, we did not detect changes in synaptic density or
cross-sectional lengths of the synaptic junctions, quantified from
electron photomicrographs using the size-frequency method
[29,30]. Thus, the cognitive enhancement induced by FGL is
not associated with detectable structural changes in CA1 stratum
radiatum synapses.
FGL Enhances Excitatory Synaptic Transmission by
Inducing AMPAR Synaptic Delivery
We then reasoned that the effect of FGL on cognition may
result from functional rather than structural changes in hippo-
campal synapses. To test the effect of FGL on synaptic
transmission, we added FGL (10 mg/ml) to the medium of
organotypic hippocampal slice cultures. After 24 h, the culture
medium was replaced with fresh medium without FGL, and the
slices were kept in culture for an additional 24 h before
electrophysiological recordings (see Materials and Methods).
Therefore, the electrophysiological responses were evaluated
48 h after the onset of the FGL treatment. This regimen was
intended to mimic the in vivo behavioral experiments, in which
stimulation of Trex293 cells that express Strep-tagged human FGFR1 with different concentrations of FGL and 10 ng/ml FGF1 (positive control) for
20 min. Bottom: Quantification of FGFR1 phosphorylation by FGL was performed by densitometric analysis of band intensity from four independent
experiments similar to the one shown in the upper panel. (C) Phosphorylation of FGFR1 and TrkB was examined from hippocampal homogenates
with an enzyme-linked immunosorbent assay (ELISA) 1 h after FGL subcutaneous injection. N, number of animals. Results are expressed as
percentage 6 SEM, with untreated controls set at 0%. (D–F) Phosphorylation of PLCc (D), Shc (E), and FRS2 (F) in vitro was examined by Western blot,
as described in Figure 1B. Treatment with FGF1 served as the positive control. Results from four independent experiments are expressed as a
percentage 6 SEM, with untreated controls set at 100%. *p,0.05, **p,0.01, ***p,0.001 compared with controls. Statistics were carried out
according to the t test.
doi:10.1371/journal.pbio.1001262.g001
Figure 2. FGL enhances spatial learning. (A) Mean distances swam
to find the hidden platform in the Morris water maze are represented
for control rats (white symbols) and FGL-treated rats (black symbols)
over 2 training days (four trials each). N, number of animals. Statistical
significance was analyzed with repeated-measures ANOVA. (B) Cumu-
lative frequency distributions of the distances swam by individual rats.
Each data point represents the distance swam by one rat in the last trial
of each day.
doi:10.1371/journal.pbio.1001262.g002
AMPA Receptors and Enhanced Cognition
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cerebrospinal fluid (CSF) [13]. We placed the stimulating
electrodes over Schaffer collateral fibers and recorded CA3-to-
CA1 synaptic transmission. Synaptic responses were evoked at
260 mV and +40 mV holding potentials, in the presence of the c-
aminobutyric acid-A (GABAA) receptor antagonist picrotoxin to
obtain separate AMPAR- and NMDAR-mediated responses, and
we calculated the ratio between these values (AMPA/NMDA
ratio). As shown in Figure 4A, the AMPA/NMDA ratio of
synaptic responses significantly increased after FGL treatment
compared with control neurons. Similarly, we obtained AMPA/
GABA ratios by evoking synaptic responses at 260 mV and 0 mV
holding potentials in the presence of the NMDAR antagonist AP5.
Similar to AMPA/NMDA ratio, we found a significant increase in
the AMPA/GABA ratio after FGL treatment compared with
control neurons (Figure 4B). Finally, we calculated NMDA/GABA
ratios by recording NMDA responses at 260 mV in the absence
of Mg
2+ and in the presence of CNQX (AMPA receptor
antagonist), and GABA responses at 0 mV. As shown in
Figure 4C, NMDA/GABA ratios were unaltered by the FGL
treatment. Additionally, FGL did not change the presynaptic
properties of excitatory transmission assessed by paired-pulse
facilitation (Figure 4D), or the passive membrane properties of the
neuron, assessed by their input resistance and holding current
(Figure S2). In conclusion, these results suggest that FGL produces
a functional postsynaptic change at excitatory CA1 synapses,
specifically an increase in AMPAR-mediated synaptic transmis-
sion.
Enhanced AMPAR synaptic responses may be attributable to
an increased number of AMPARs at synapses or a functional
modification of preexisting synaptic receptors. To directly
determine whether FGL induces the delivery of new AMPARs
into synapses, we expressed the GluA1 subunit of AMPARs tagged
with GFP (GluAl-GFP) in CA1 neurons in organotypic hippo-
campal slice cultures (Figure 5A–B). We employed this subunit
because it has been previously shown that newly synthesized
GluA1-containing AMPARs are not spontaneously inserted at
synapses, unless driven by strong synaptic stimulation or activation
of specific signaling pathways associated with LTP induction
[22,31]. In addition, overexpressed GluAl-GFP subunits form
homomeric AMPARs, whose presence at synapses can be assessed
from their inward rectification properties (electrophysiological
tagging [31]). GluA1-GFP was expressed in organotypic slice
cultures for 60 h (24 h of FGL treatment plus 36 h in fresh
medium), and synaptic delivery was quantified as an increase in
the ratio of the evoked postsynaptic current at 260 mV relative to
the current at +40 mV (rectification index, RI=I260/I+40), in the
presence of the NMDAR antagonist AP5. We found that FGL
treatment increased the rectification index in neurons that express
GluA1-GFP (Figure 5C). This result strongly suggests that FGL
induces synaptic delivery of AMPARs. To note, FGL treatment
alone did not change the rectification index in the absence of
GluA1-GFP expression (Figure 5C, ‘‘FGL uninfected’’ versus
‘‘Untreated control’’), indicating that FGL does not alter the
intrinsic rectification properties of endogenous AMPA receptors.
Also, GluA1-GFP is not delivered spontaneously into synapses
[31].
Altogether, these results indicate that FGL enhances excitatory
synaptic transmission by inducing the insertion of new AMPARs
at synapses. It is also important to point out that FGL is removed
from the culture medium from 24 to 36 h before the electrophys-
iological recordings, indicating that FGL induces long-lasting
changes in synaptic transmission.
The PKC Pathway Mediates FGL-Induced Synaptic
Incorporation of AMPARs
After establishing the specific synaptic modification produced
by FGL (enhanced AMPAR synaptic delivery), we identified the
underlying signal transduction mechanism. Hippocampal slices
were treated with FGL while blocking the three pathways
downstream from FGFR activation that may modulate AMPAR
trafficking (i.e., the MAPK, PI3K, and PKC pathways). As a
reporter for AMPAR synaptic delivery, we monitored inward
rectification of synaptic transmission in GluA1-GFP-expressing
neurons, described above. Incubation of the slice culture in
25 mM PD98059, a potent inhibitor of MAPK kinase (MEK
[32]), did not block the increase in the rectification index
induced by FGL in GluA1-GFP-expressing neurons (compare
Figure 5C,D). Therefore, we conclude that FGL-induced
AMPAR synaptic delivery does not require MAPK activation.
Similarly, incubation in 10 mM LY294002, a potent and selective
PI3K inhibitor [33], did not prevent GluA1 synaptic delivery
(Figure 5E). In contrast, 5 mM chelerythrine, a general inhibitor
of PKC [34], did block the FGL-induced increase in rectification
(Figure 5F) (the efficacy of chelerythrine as a specific PKC
inhibitor is evidenced from the blockade of MARCKS
phosphorylation and its translocation from the plasma mem-
brane to the cytosol in response to PKC activation; see Figure
S3). This finding indicates that FGL enhances AMPAR synaptic
delivery in a PKC-dependent manner. Moreover, incubation of
slices with a selective inhibitor of classical PKC isoforms (a, b,
and c) (200 nM GF109203X [35]) also blocked the increase in
the rectification index (Figure 5G), whereas a specific inhibitor of
atypical PKC isoforms (1 mM zeta inhibitory peptide [ZIP]) did
not (Figure 5H).
Therefore, these findings indicated that of the multiple signaling
pathways potentially triggered by FGL, the synaptic delivery of
AMPARs with the consequent potentiation of synaptic transmis-
sion is mediated by PKC activation, specifically by classical PKC
isoforms. These results are consistent with the failure of FGL to
induce the phosphorylation of FRS2 (Figure 1F), which acts as an
Figure 3. Unchanged morphological parameters after FGL treatment. (A) Fluorescence image of CA1 pyramidal neuron injected with Lucifer
Yellow (green). DAPI nuclear staining (blue) was used to facilitate intracellular injection into the soma. Bar=50 mm. (B) Confocal projection image of
CA1 pyramidal neurons (left) and the same neuron processed for DAB staining (right). Bar=20 mm. (C) High-magnification images of representative
spiny dendrites. Bar=10 mm. (D) Quantification of spine density from stratum radiatum CA1 dendrites. N, number of animals. (E) Quantification of
spine density sorted by branch order (1–4) of the oblique apical dendrite. (F) Maximum-projection confocal images of a basal CA1 dendritic segment
before (left) and after (right) the blind deconvolution protocol (10 iterations). Bar=1 mm. (G) Maximum-projection image of a dendrite after blind
deconvolution (left) and the same dendritic segment with marked spine heads (red) as used to measure head volumes (right). Bar=2 mm. (H) Higher
magnification of a short dendritic segment that shows the measurements of each spine (i.e., spine head volume and neck length). Bar=0.5 mm. (I)
Quantification of spine head volume in FGL and control rats. N, number of animals. (J) Cumulative frequency of spine head volume from the same
data as in (I). N, number of spines. (K) Electron micrographs that show a representative neuropil in the stratum radiatum. Symmetric and asymmetric
synapses were identified to quantify synaptic density using unbiased stereology. Bar=0.5 mm. (L) Quantification of synaptic density in FGL and
control rats. N, the number of animals. (M) Cumulative frequency of postsynaptic density length. N, number of synaptic profiles.
doi:10.1371/journal.pbio.1001262.g003
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PLoS Biology | www.plosbiology.org 6 February 2012 | Volume 10 | Issue 2 | e1001262Figure 4. Enhanced postsynaptic excitatory transmission in neurons treated with FGL. (A) Average AMPA/NMDA ratios for treated and
untreated cells. AMPAR-mediated responses were recorded at 260 mV, and NMDAR-mediated responses were recorded at +40 mV. The p value was
determined using the Mann-Whitney test. (B) Average AMPA/GABA ratios for treated and untreated cells. AMPAR-mediated responses were recorded
at 260 mV, and GABA-mediated responses were recorded at +0 mV. NMDAR were blocked with DL-AP5. The p value was determined using a t test.
Representative traces appear above the corresponding bars. N, number of cells. (C) Average NMDA/GABA ratios for treated and untreated cells.
AMPA Receptors and Enhanced Cognition
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pathways [36,37].
FGL Facilitates NMDAR-Dependent LTP in a PKC-
Dependent Manner
The synaptic incorporation of AMPAR induced by FGL may
be directly driven by PKC activation and AMPAR phosphoryla-
tion [22] or, alternatively, may be an activity-dependent process
that is facilitated by FGL. This is an important distinction, because
a cognitive enhancer would be expected to modulate synaptic
function in a synapse-specific manner. The classic paradigm for
activity-dependent synaptic delivery of AMPARs is NMDAR-
dependent LTP. Therefore, we hypothesized that FGL induces an
LTP-like process in response to spontaneous synaptic activity in
hippocampal slices. Notable, spontaneous activity in organotypic
slice cultures is typically not sufficient to induce the synaptic
delivery of AMPARs [31]. To determine whether FGL-induced
synaptic potentiation resembles conventional LTP processes,
AMPAR delivery was examined by monitoring inward rectifica-
tion (described for Figure 5) after blocking NMDARs or CaMKII.
We found that 100 mM AP5, a competitive NMDAR antagonist,
completely blocked the FGL-induced delivery of tagged AMPARs
into synapses (Figure 6A). Similarly, 20 mM KN-93, a potent
inhibitor of CaMKII catalytic activity [38], blocked FGL-induced
AMPAR synaptic delivery (Figure 6B, left panel). In contrast, the
inactive analog KN-92 did not block AMPAR synaptic delivery, as
detected by the increase in the rectification index in FGL-treated
slices (Figure 6B, right panel). Therefore, FGL-triggered AMPAR
delivery depends on the NMDAR and CaMKII activity.
Since FGL-induced synaptic potentiation appears to mimic
classic NMDAR-dependent LTP, we decided to test whether FGL
affects this form of synaptic plasticity. Similar to the previous
experiments, slices were pretreated with FGL for 24 h. The
culture medium was then changed (without FGL), and recordings
were performed 24 h later. Therefore, as in the previous
experiments, electrophysiological experiments start 48 h after the
onset of FGL treatment. LTP was induced in CA1 neurons by
pairing 3 Hz presynaptic stimulation of the Schaffer collaterals
with 0 mV postsynaptic depolarization as previously described
[31]. As shown in Figure 6C–E, LTP induction significantly
increased AMPAR-mediated responses in both FGL-treated and
untreated neurons. Nevertheless, FGL treatment dramatically
enhanced LTP expression (3.5-fold potentiation with FGL versus
2-fold potentiation in control neurons; see also Figure S4 for a
complete distribution of individual LTP experiments).
To determine whether FGL-induced LTP enhancement occurs
through mechanisms similar as FGL-induced GluA1 synaptic
delivery, we tested the role of PKC activation in this process. Slices
were incubated with 5 mM chelerythrine together with FGL.
Electrophysiological recordings were then performed without
chelerythrine because PKC activity is required for LTP induction
[39]. Notably, the magnitude of LTP after treatment with FGL in
the presence of chelerythrine (Figure 6C–E, ‘‘FGL+Chel’’) was
indistinguishable from LTP in untreated neurons, suggesting that
PKC activity is required for the enhancing effect of FGL. As a
control, neurons treated with chelerythrine alone had similar LTP
levels as untreated neurons (Figure 6C–E, ‘‘Chel’’), indicating that
prior PKC activity is not required for subsequent LTP induction.
Finally, FGL did not have any effect on the non-potentiated
(unpaired) pathway (Figure 6F). As mentioned above, FGL (and
chelerythrine) were washed out from the slices 24 h before
performing the LTP experiments. Therefore, these data indicate
that FGL produces a long-lasting, PKC-dependent enhancement
of LTP.
After having established the effect of FGL on synaptic
potentiation, we wished to test whether FGL affects LTD, another
NMDAR-dependent form of synaptic plasticity. Similar to the
previous experiments, slices were pretreated with FGL for 24 h.
The culture medium was then changed (without FGL), and
recordings were performed 24 h later. LTD was induced in CA1
neurons by pairing 1 Hz presynaptic stimulation of the Schaffer
collaterals with moderate postsynaptic depolarization (240 mV),
as previously described [40]. As shown in Figure S5, LTD
induction produced a similar decrease in AMPAR-mediated
responses in both FGL-treated and untreated neurons. Therefore,
we conclude that the enhancement of synaptic plasticity produced
by FGL is specific for synaptic potentiation.
It has been reported that NMDARs with different subunit
composition play specific roles in different forms of synaptic
plasticity, although the details of this specificity are still under
debate [41,42]. As an initial attempt to test whether FGL may
alter the subunit composition of NMDARs, we evaluated the
kinetics of NMDAR-mediated responses, since NR2A- and
NR2B-containing NMDARs display distinct decay time constants
[43]. As shown in Figure S6, NMDA responses from FGL-treated
neurons displayed faster decay kinetics than those from untreated
neurons. However, this effect was not blocked by incubation with
chelerythrine to inhibit the PKC pathway (Figure S6,
‘‘FGL+Chel’’). Therefore, even if FGL alters NMDAR subunit
composition, this effect does not appear to be mechanistically
linked to the enhancement of LTP and AMPAR synaptic delivery,
which require PKC activity. Therefore, we have not pursued this
effect any further.
FGL Does Not Alter Spine Structural Plasticity
Synaptic potentiation has been shown to be accompanied by an
increase in spine size and recruitment of polymerized actin into the
spine head [44]. Therefore, we tested whether FGL enhances this
form of structural plasticity as it enhances synaptic potentiation.
To this end, we expressed GFP-actin in organotypic hippocampal
slices, and then induced LTP using a pharmacological approach
that allows us to maximize the number of synapses undergoing
plasticity, while mimicking biochemical and electrophysiological
properties of electrically induced LTP [45]. As shown in Figure S7,
LTP induction led to an increase in actin-GFP recruitment into
spines, which was similar in extent between control and FGL-
treated spines (these experiments were analyzed blind with respect
to the treatment the slices had received). Therefore, FGL
treatment enhances synaptic potentiation, without altering the
capacity of spines to undergo structural plasticity, at least as
monitored by actin recruitment into the spine head.
NMDAR-mediated responses were recorded at 260 mV in the absence of Mg
2+ and in the presence of CNQX to block AMPARs. GABA-mediated
responses were recorded at 0 mV. The p value was determined using a t test. Representative traces appear above the corresponding bars. N, number
of cells. (D) Paired-pulse facilitation (PPF) in FGL and control neurons. The values denote the ratio of the second EPSC amplitude to the first EPSC
amplitude. PPF was tested for 50-, 100-, 200-, and 400-ms interstimulus intervals. Insets. Sample trace of evoked AMPAR-mediated synaptic responses
with an interstimulus interval of 50 ms. N, number of cells. Scale bars: 10 pA, 50 ms.
doi:10.1371/journal.pbio.1001262.g004
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Treatment
The experiments above indicate that the enhancing effect of
FGL on synaptic plasticity does not require the continuous
presence of FGL because it can last at least 24 h after FGL
removal. This is also consistent with the behavioral effects of FGL
treatment, which were manifested 2 d after FGL application
(Figure 2). Therefore, we sought long-lasting biochemical
signatures of FGL treatment by preparing whole-cell extracts
from hippocampal slices at different times after adding FGL to the
culture medium, and after its removal 24 h later. We then used
Western blot to evaluate three key events linked to upstream FGL
action and downstream LTP-related signaling: (i) PKC activation
(presumably triggered directly by FGL upon FGFR activation and
PLCc phosphorylation; Figure 1D), (ii) CaMKII phosphorylation
(downstream from NMDAR opening and key mediator of LTP
expression [46]), and (iii) GluA1 Ser
831 phosphorylation (triggered
during LTP upon CaMKII activation [47] but also catalyzed by
PKC [48]).
To evaluate global PKC activation, we monitored the
phosphorylation of multiple PKC substrates with an antibody
that recognizes a phospho-Ser PKC substrate motif. Phosphory-
lation of CaMKII at Thr
286 and GluA1 at Ser
831 was monitored
with the corresponding phospho-specific antibodies (see Materials
and Methods). As shown in Figure 7A, FGL application led to
rapid (5–20 min) upregulation of the PKC pathway, which was
expected from the activation of FGFR and PLCc (Figure 1D).
Moreover, this pathway remained activated throughout the FGL
treatment and 24 h after its removal (Figure 7A, the ‘‘48 h’’
column represents slices treated with FGL for 24 h and then
transferred to fresh medium without FGL for 24 h more).
Interestingly, CaMKII activation (monitored by Thr
296 phosphor-
ylation) was transiently decreased by FGL (20–30 min after
application), but it showed a gradual upregulation at late time-
points, including 24 h after FGL removal (Figure 7B, gray
columns). Finally, GluA1 phosphorylation at Ser
831 was induced
early after the addition of FGL but also persisted by the end of the
time course (Figure 7C, gray columns). The total levels of CaMKII
and GluA1 did not significantly change during or after FGL
application (Figure 7B–C, black columns).
These results strongly suggest that FGL initiates signaling
mechanisms that outlast the initial triggering events. These
mechanisms may be related to a sustained enhanced synaptic
activity in the slices, as a consequence of GluA1 delivery.
Cognitive and Synaptic Effects of FGL Share the PKC
Pathway
We showed that enhanced synaptic delivery of AMPARs and
LTP are induced by FGL in a PKC-dependent manner. We then
hypothesized that if facilitated AMPAR synaptic incorporation
and LTP contribute to the enhanced cognitive effects of FGL, then
blocking the PKC pathway should also block the effects of FGL on
learning. To test this point, rats were stereotactically implanted
with a double-cannula into the lateral cerebral ventricles. They
were then divided into four experimental groups (n=10–14/
group) according to treatment (total administered volume, 5 ml): (i)
vehicle (artificial CSF [ACSF]), (ii) vehicle +20 mg FGL, (iii) 20 mg
FGL +2.5 nmol chelerythrine, and (iv) vehicle +2.5 nmol
chelerythrine. Drugs were injected 5 d, 3 d, and 1 d before
training. The experimenter who trained the rats was blind to
treatment. No side effects were observed following any of the
treatments. Because performance of vehicle- and chelerythrine-
treated rats was similar in this task (F1,10=0.6, p=0.4), data from
these two control groups were pooled (see average data in Figure
S8A). There were significant differences in the learning curves
among the remaining groups (repeated measure ANOVA:
F2,22=12.79, p=0.001). Similar to our observations with
subcutaneous FGL administration (Figure 2), FGL-treated rats
(FGL+vehicle) outperformed their controls (vehicle) in the water
maze throughout the training procedure (Bonferroni’s post hoc
test: p,0.05 for trials 3 and 7; Figure 8A). Notably, FGL did not
enhance learning when combined with chelerythrine (FGL+che-
lerythrine), indicating that the effects of FGL on cognition depend
on PKC activity (Bonferroni’s post hoc test: p,0.05, for the
comparison between FGL+vehicle versus FGL+chelerythrine, for
trials 3, 4, and 7). Similar blind experiments were separately
carried out with the specific inhibitor of classical PKC isoforms
GF109203X. Consistent with our experiments with chelerythrine,
co-injection of GF109203X (1 nmol in 5 ml) with FGL blocked the
enhanced performance produced by the peptide alone (Figure 8B)
(vehicle- and GF109203X-treated rats were similar in this task,
and these two control groups were pooled; see separate data in
Figure S8B). Finally, similar experiments were attempted with
MEK and PI3K inhibitors (PD98059 and LY294002, respective-
ly), but these data could not be easily interpreted due to the
intrinsic effect of these drugs on the behavioral task (see Figure S9).
FGL has also been shown to enhance memory consolidation
when administered immediately after training [12]. We then tested
whether the cognitive effects of FGL on memory were also
mediated by the same signaling pathway as the synaptic and
learning effects. To this end, rats were stereotactically implanted
with cannulae as in the previous experiment, but FGL (with or
without chelerythrine) was administered immediately after the
training session of each day (see Materials and Methods). Spatial
memory was then tested 24 h after the second training day. As
shown in Figure 8C, FGL was able to enhance memory under
these conditions, as previously described. Most importantly, this
enhancement was blocked when FGL was co-administered with
chelerythrine, indicating that PKC is also required for FGL-
induced memory enhancement.
In conclusion, these behavioral experiments testing the effect of
FGL on both learning and memory indicated that enhanced
cognition depends on the PKC pathway, similarly to enhanced
AMPAR synaptic delivery and LTP. These results strongly suggest
that synaptic and cognitive effects of FGL are mechanistically
linked.
Figure 5. FGL induces AMPA receptor synaptic delivery via PKC activation. (A) Left: CA1 pyramidal neurons that express GluA1-GFP (green)
on a DAPI-stained (blue) organotypic slice culture, imaged with laser-scanning confocal microscopy. Bar=50 mm. Right: High-magnification image of
GluA1-GFP-expressing neurons. Bar=20 mm. (B) Schematic diagram that presents whole-cell recordings obtained from a neuron expressing GluA1-
GFP (infected, green) and an adjacent non-fluorescent (uninfected, white) neuron. (C) AMPAR-mediated responses were recorded at 260 mV and
+40 mV. The rectification index was calculated as the ratio of responses at these holding potentials. The p value was determined using the Mann-
Whitney test. (D–H) FGL-induced rectification after incubation with inhibitors of different signal transduction pathways: MEK, PD98059 (D); PI3K,
LY294002 (E); PKC, chelerythrine (F); classical PKC isoforms, GF109203X (G); atypical PKC isoforms (H). Sample traces are shown above the
corresponding columns of the plot. N, number of cells. The p value was determined using the Mann-Whitney test. Scale bars=15 pA and 10 ms.
doi:10.1371/journal.pbio.1001262.g005
AMPA Receptors and Enhanced Cognition
PLoS Biology | www.plosbiology.org 10 February 2012 | Volume 10 | Issue 2 | e1001262AMPA Receptors and Enhanced Cognition
PLoS Biology | www.plosbiology.org 11 February 2012 | Volume 10 | Issue 2 | e1001262Discussion
In this work, we have described a specific molecular mechanism
and signaling pathway by which the NCAM mimetic peptide FGL
produces a long-lasting enhancement of synaptic plasticity that
leads to improved spatial learning and memory. We propose that
the facilitation of AMPAR synaptic delivery during learning-
induced plasticity events underlies the enhanced cognition
produced by FGL. Interestingly, these effects were persistent,
and outlasted the initial FGL stimulus. These conclusions are
based on three major lines of evidence. First, we showed that FGL
produces a long-lasting potentiation of synaptic transmission in
hippocampal slices, based on the facilitated synaptic delivery of
AMPARs upon NMDAR activation. Second, we found that
synapses remain ‘‘sensitized’’ for further LTP induction long after
FGL is cleared from the system. Third, both the synaptic and
behavioral effects of FGL are based on a long-lasting increase in
PKC activity, which is accompanied by a persistent activation of
the CaMKII pathway.
A particular novelty of this work relies on linking a direct
synaptic modification (i.e., facilitation of AMPAR synaptic
delivery) with a high-order cognitive effect (i.e., enhanced spatial
learning). Importantly, FGL is acting as a facilitator, rather than a
direct trigger, for AMPAR synaptic insertion. That is, FGL-
induced potentiation still remains activity-dependent, because it
requires NMDAR and CaMKII activation. In fact, it appears that
FGL is sensitizing the ‘‘classical’’ LTP pathway, because
spontaneous neuronal activity is then able to trigger AMPAR
delivery and stabilize synaptic potentiation. This mechanism
differs significantly from other neurotrophin-related synaptic
modulators, such as BDNF or tumor necrosis factor-a (TNFa),
which trigger AMPAR synaptic delivery while bypassing standard
LTP signaling [49,50]. This is a significant distinction, because an
effective cognitive enhancer may be expected to facilitate synaptic
plasticity events, rather than provoke them in a manner unrelated
to ongoing circuit activity. We also want to point out that FGL is
acting as a synaptic and cognitive enhancer over physiological
levels. That is, FGL treatment increases the extent of synaptic
potentiation in naive hippocampal slices, and similarly, it enhances
the potential for spatial learning in healthy, young adult rats.
These results emphasize the notion that synaptic and cognitive
mechanisms can be tuned to operate above normal physiological
parameters.
From a mechanistic perspective, it is interesting that FGL
produces a persistent enhancement of synaptic plasticity and
learning. Thus, we found that a transient activation of FGFR-
NCAM signaling by FGL results in long-lasting activation of the
PKC and CaMKII pathways, accompanied by enhanced LTP and
spatial learning observed 24–48 h after the removal of FGL. We
have also determined that the establishment of this persistent
enhancement requires PKC activity during the action of FGL. In a
sense, this sensitized state produced by FGL is reminiscent of what
has been termed metaplasticity (i.e., a persistent modification that
alters the ability of the synapse to undergo further plasticity events
[51]). There is a wide variety of mechanisms that may shift the
sensitivity to synaptic plasticity induction, ranging from structural
alterations in the extracellular matrix [52] to changes in NMDAR
subunit composition [53] or metabotropic glutamate receptor
activation [54]. With regard to FGL and the subsequent activation
of FGFR-NCAM signaling, we determined that the functional
synaptic changes are not accompanied by detectable alterations in
morphology of dendritic spines, ultrastructural synaptic organiza-
tion, or presynaptic release properties (this is in contrast with the
reported effects of FGL on synaptogenesis and presynaptic
function on primary neuronal cultures [12]). On the other hand,
we established that PKC activity is required to reach this sensitized
state, followed by a long-lasting increase in CaMKII activity and
AMPAR phosphorylation at GluA1 Ser
831. Interestingly, these
changes do not saturate (or occlude) further LTP expression. In
fact, the potential for LTP expression is actually enhanced after
FGL treatment. These considerations lead us to propose a model
in which FGL-triggered FGFR-NCAM signaling acts on upstream
targets that facilitate LTP induction. Subsequently, ongoing
neuronal activity will be more likely to activate NMDARs and
CaMKII, leading to enhanced synaptic delivery of AMPARs and
potentiation of synaptic responses. This strengthening of excitatory
connections may in turn facilitate the induction of further LTP-
like events, resulting in the observed long-lasting increase in PKC
and CaMKII activation, and AMPAR phosphorylation. These
synaptic and biochemical changes will persist, as long as there is
ongoing neuronal activity in the circuit.
In conclusion, the present study has provided mechanistic
insights into the synaptic events and molecular cascades that
mediate the enhanced cognitive function produced by a
pharmacological mimetic of cell adhesion-growth factor signaling.
Materials and Methods
For a more detailed description of the methods, see Text S1.
FGL Preparation
The pentadecapeptide FGL (EVYVVAENQQGKSKA), cor-
responding to residues E681 to A695 of the second fibronectin
domain of NCAM (Figure 1A), was synthesized using 9-
fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis
methodology. FGL was used in dimeric form by linking two
monomers through their N-terminal ends with iminodiacetic acid
(N-carboxymethyl)-glycine (Polypeptide Laboratories, Hillerød,
Denmark). This dimeric design binds and brings together two
FGFR molecules, which is crucial for receptor phosphorylation
and downstream signaling [55]. The C-terminal ends of the
peptides were amidated. The peptide was at least 85% pure as
estimated by high-performance liquid chromatograhy.
Figure 6. FGL enhances long-term synaptic potentiation. (A–B) Rectification experiments similar to the ones described in Figure 5, after
incubation with DL-AP5 (NMDAR inhibitor), KN-93 (CaMKII inhibitor), or KN-92 (inactive analog of KN-93). Sample traces are shown above the graphs.
(C) Sample traces of evoked AMPAR-mediated synaptic responses recorded from CA1 neurons at 260 mV before (thin line) and after (thick line) LTP
induction. LTP was induced by pairing presynaptic 3 Hz stimulation (540 pulses) with postsynaptic depolarization (0 mV). One of the stimulating
electrodes was turned off during LTP induction (‘‘unpaired pathway’’). Organotypic slice cultures were incubated with (i) normal culture medium
(control), (ii) FGL, (iii) the PKC inhibitor chelerythrine (Chel), or (iv) FGL and chelerythrine (FGL+Chel), as indicated. Treatments were for 24 h and slices
were transferred to fresh culture medium (without FGL or chelerythine) for an additional 24 h prior to recordings. (D) Time course of normalized
AMPAR-mediated synaptic responses before and after LTP induction (black arrow), from the slices treated as in (C). For simplicity, each time point in
the plot corresponds to the average of 12 consecutive stimulations (sampling rate: 0.2 Hz). (E–F) Quantification of average synaptic potentiation from
paired (‘‘LTP’’) and unpaired pathways from the last 10 min of the time-course shown in (D). The p value was determined with the Mann-Whitney test.
N, number of cells.
doi:10.1371/journal.pbio.1001262.g006
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PLoS Biology | www.plosbiology.org 12 February 2012 | Volume 10 | Issue 2 | e1001262Figure 7. FGL-triggered persistent activation of signaling pathways. (A) Left: Western blot of hippocampal extracts treated with TPA (12-O-
tetradecanoylphorbol-13-acetate; PKC activator that served as a positive control), untreated (‘‘0’’), and treated with FGL at different time-points after FGL
application. The primary antibody detects phosphorylation of endogenous proteins at PKC substrate motifs (phospho-(Ser) PKC substrate). Right:
Quantification of Western blots similar to the one shown on the left, by calculating the combined intensity from all bands in each lane. N, number of
independent experiments. The p values were determined withthe Mann-Whitney test.(B, C) Left:Western blotofhippocampal extractstreated with FGLat
different time-points after FGL application and untreated (‘‘0’’). The primary antibodies detected phosphorylated CaMKII at Thr286 (p-CaMKII) andt o t a l
levels of CaMKII (T-CaMKII)(B), or phospho-GluA1 (P-S831) and total GluA1 (C). Tubulin was used as a loading control. Right:Quantificationof Western blots
similar to the ones shown on the left. N, number of independent experiments. The p values were determined using the Mann-Whitney test.
doi:10.1371/journal.pbio.1001262.g007
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Subcutaneous FGL administration. Male Wistar rats
(Harlan, Barcelona, Spain) between 8 and 9 wk of age (weighing
240–260 g) were subcutaneously injected with FGL (6.6 mg/kg
body weight) orvehicle (0.9%NaCl) alone,5 and 2 d before training
began (for behavioral testing) or before sacrifice (for morphological
experiments). For the biochemical experiments (FGFR1 and TrkB
phosphorylation), a single FGL/vehicle injection was administered
1 h before sacrifice at a dose of 2.2, 6.6, or 8.8 mg/kg body weight.
No side effects were observed following these treatments.
Intracerebroventricular injection procedure. Approximately
2 wk after arrival, rats were prepared for intracerebroventricular
cannulation. Rats were anesthetized intraperitoneally with 2,2,2-
tribromomethanol (250 mg/kg, Aldrich, Milwaukee, WI). A 22-gauge
double-guide injection cannula (C313G, Plastic One, Roanoke, VA)
fitted with a removable dummy cannula was stereotactically implanted
into the lateral cerebral ventricles 1.3 mm posterior, 1.6 mm lateral,
and 3.5 mm ventral, and fixed with two screws in the skull using dental
cement (Duralay 2244, Reliance). At least 12 d were allowed for
recovery from surgery before any behavioral test. After surgery, the
animals were housed in pairs, and their body weights were monitored.
Protein kinase inhibitors were prepared in an aCSF vehicle
solution, with 1% DMSO (chelerythrine), 20% cyclodextrane
(GF109203X), or 1% DMSO plus 20% cyclodextrane (PD98059
and LY294002). FGL was always prepared in the same vehicle
solution as the kinase inhibitors present in the corresponding
experiment. A flexible swivel attached to the rat allowed the
peptide to be administered while the animal was conscious and
freely moving in a cage. For learning experiments (Figures 2 and
8A, B), FGL was applied 5, 3, and 1 d before water maze training.
For memory experiments (Figure 8C), FGL was infused immedi-
ately after each training session. The dummy cannula was
removed and replaced with a 28-gauge infusion cannula (model
C313I, Plastics One, Roanoke, VA) attached to a 2.5 ml Hamilton
syringe via polyurethane tubing (fluorinated ethylene propylene,
0.12 mm diameter CMA, Microdialysis AB, Stockholm, Sweden).
A microinjection pump (Harvard Apparatus, Cambridge, MA)
controlled the delivery of 5 ml of solution through the cannulas at a
rate of 1.25 ml/min. The cannulas were left in place for an
additional 3 min to allow diffusion of the peptide away from the
cannula tip before replacement with the dummy cannula. All rats
were habituated to this injection procedure (i.e., no solution was
injected) for 2 min daily for 2 d preceding the proper injection on
the day of the experiment.
All biosafety procedures and animal care protocols were
approved by the bioethics committee from the Consejo Superior
de Investigaciones Cientificas (CSIC), and were carried out
according to the guidelines set out in the European Community
Council Directives (86/609/EEC).
Behavior
Morris water maze spatial learning was performed under mild
training conditions to assess any modulation of learning related to
FGL administration. For details, see Text S1.
Biochemistry
Protein extracts from hippocampal slices were prepared in
10 mM HEPES, 150 mM NaCl, 10 mM EDTA, 0.1 mM
phenylmethanesulphonylfluoride (PMSF), 2 mg/ml chymostatin,
2 mg/ml leupeptin, 2 mg/ml antipain, 2 mg/ml pepstatin, 10 mM
NaF, 1 mM microcystin LR, 0.5 mM calyculin A, and 1% Triton
X-100. Western blots were developed with chemiluminescence
(SuperSignal Kit; Pierce, Rockford, IL) and quantified using a
densitometric scanning under linear exposure conditions.
Figure 8. FGL-induced enhanced cognition depends on PKC
activity. (A, B) Mean distances traveled to find the hidden platform in
the Morris water maze are represented for control rats (white circles),
FGL-treated rats (black circles), and rats treated with FGL and the PKC
inhibitor (grey squares; A, chelerythrine; B, GF109203X), over the 2
training days (four trials each). N, number of animals. Statistical
significance was analyzed with repeated-measures ANOVA followed
by Bonferroni’s post hoc test for individual trials. A: *p,0.05, FGL+Veh
compared to FGL+Chel and Veh/Chel groups. #p,0.05, FGL+Veh
compared to FGL+Chel but not compared to Veh/Chel. B: *p,0.05,
FGL+Veh compared to FGL+GF109203X and Veh/GF109203X groups.
#p,0.05, FGL+Veh compared to Veh/GF109203X but not compared to
FGL+GF109203X. (C) Probe test. Average time spent in the target
quadrant of the Morris water maze (where the hidden platform had
been present during training) for control rats (white column), FGL-
treated rats (black column), or rats treated with FGL plus chelerythrine
(grey column). Statistical significance was calculated with Bonferroni’s
post hoc test.
doi:10.1371/journal.pbio.1001262.g008
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with anti-phospho-FGFR-1 (pYpY653/654, Biosource International),
anti-phospho-TrkB (Abcam), anti-phospho-GluA1 (P-S831 and P-
S845, Upstate Biotechnologies), anti-total GluA1 (Abcam), anti-
phospho-CaMKII (Thr286, Chemicon), and anti-total CaMKIIa
(Sigma). PLCc1, phospho-PLCc1 (Tyr783), FRS2a, phospho-FRS2a
(Tyr436), ShcA, phospho-ShcA (Tyr239/240), MARCKS and
phospho-MARCKS (Ser152/156) antibodies were obtained from
Cell Signalling. Strep II tag antibody was from QIAGEN
(Copenhagen, Denmark). Agarose-coupled anti-phosphotyrosine
antibody (4G10-AC) was from Upstate Biotechnologies.
Fluorescence Microscopy
Rats (n=8/group) were perfused with 4% paraformaldehyde
(pH 7.4). Coronal sections (150 mm) were cut on a vibratome.
Cells in the hippocampus were individually injected with Lucifer
Yellow. Imaging was performed on a Leica laser scanning
multispectral confocal microscope (TCS SP5) using an argon
laser. After acquisition, the stacks were processed with a 3-
dimensional blind deconvolution algorithm (Autodeblur; Auto-
quant, Media Cybernetics) to reduce the out-of-focus light (see
example in Figure 3F). The 3-dimensional image processing
software IMARIS 5.0 (Bitplane AG, Zurich, Switzerland) was used
to measure the spine head volume and neck length (see also Text
S1) [30]. For spine density analysis, dendrites were traced with the
Neurolucida 7.1 computerized data collection system. Spine
density was automatically calculated by dividing the number of
spines on a dendrite by the dendrite length. See Text S1 for
further details.
Electron Microscopy
Sections adjacent to those used for the intracellular injections
were processed for electron microscopy. These sections were
embedded in Araldite and studied using a correlative light and
electron microscopic method (described in detail in Text S1). The
two major morphological types of cortical synapses, namely
asymmetrical and symmetrical types [29], were clearly identified
in the analyzed tissue. The synapses in which the synaptic cleft and
associated membrane densities could not be visualized clearly
because of the oblique plane of the section were considered
uncharacterized synapses. Synaptic density per unit area (NA) was
estimated from electron microscope samples of neuropil of the
stratum radiatum of CA1. The density of synapses per unit volume
of the neuropil was calculated using the formula NV=NA/d,i n
which NA is the number of synaptic profiles per unit area and d is
the average cross-sectional length of synaptic junctions (for a
detailed description, see [29]).
Organotypic Cultures and FGL Treatment
Hippocampal slice cultures were prepared from postnatal day
5–6 rats [56]. After 4–8 d in culture, FGL was applied to the
culture medium (10 mg/ml), and the medium was refreshed,
without FGL, 24 h later. Electrophysiological recordings were
performed 2 d after beginning the FGL treatment.
Electrophysiology
Voltage-clamp whole-cell recordings were obtained from CA1
pyramidal neurons under visual guidance using fluorescence and
transmitted light illumination. For details regarding the internal
and external solutions, see Text S1. Synaptic AMPAR-mediated
responses were acquired at 260 mV. NMDAR responses were
recorded at +40 mV at a latency at which AMPAR responses were
fully decayed (60 ms after stimulation). In both cases, 100 mM
picrotoxin was present in the external solution. GABAA receptor
responses were recorded at 0 mV in the presence of 100 mM AP5
in the external solution. For the rectification studies, GluA1-GFP
was expressed in CA1 neurons for 60 h, and AMPAR responses
were recorded at 260 mV and +40 mV in the presence of
0.1 mM AP5 in the external solution and 0.1 mM spermine in the
internal solution. Because only CA1 cells (and not CA3 cells) were
infected, this configuration ensured that GluA1-GFP was always
expressed exclusively in the postsynaptic cell. When specific kinase
inhibitors were used, the inhibitor was added to the culture
medium 1 h before the addition of FGL. The medium was
refreshed 1 d later with the same inhibitor but without FGL.
Electrophysiological recordings were performed 1 d later in the
presence of the kinase inhibitor (with the exception of cheler-
ythrine, which was neither added to the medium upon refreshing
nor present during the recordings). LTP was induced using a
pairing protocol by stimulating Schaffer collateral fibers at 3 Hz
for 1.5 min while depolarizing the postsynaptic cell at 0 mV.
Whole-cell recordings were made with a Multiclamp 700A
amplifier (Axon Instruments).
Statistical Analysis
For the behavioral results, the data were analyzed with SPSS
version 11 (Chicago, IL, USA). Morris water maze training data
were analyzed across trials with one-way analysis of variance
(ANOVA), with the training trial as the repeated measure,
followed by Bonferroni’s post hoc test when appropriate. For the
morphological parameters, the data were averaged to obtain the
cell mean, and the neurons from each animal were averaged for
the animal mean. Normality was tested using the Kolmogorov-
Smirnov test. Because both the spine density and spine
morphology values had Gaussian distributions, we used a two-
tail unpaired t test to assess the overall effect. When comparing
mean electrophysiological values, statistical significance was
determined by the Mann-Whitney test (unless indicated different-
ly) if only two distributions were compared or by ANOVA
followed by the Kruskal-Wallis test if multiple distributions were
analyzed.
Supporting Information
Figure S1 Unaltered spine neck length after FGL treatment. (A)
Representative confocal projection image of CA1 pyramidal
neurons. Bar=150 mm. (B) Representative high magnification
confocal projection image of apical dendrites to illustrate dendritic
spines. Bar=1.5 mm. (C) Quantification of spine neck length
measured three-dimensionally. N, number of rats. (D) Cumulative
frequency of neck length values. N, number of spines.
(TIF)
Figure S2 Effects of FGL on passive membrane properties of
CA1 hippocampal neurons. (A–B) Application of FGL to cultured
hippocampal slices did not alter input resistance (a) or holding
current (b) when compared with untreated control neurons. N,
number of cells.
(TIF)
Figure S3 Chelerythrine inhibition of PKC activity on
MARCKS (Myristoylated Alanine-Rich C-Kinase Substrate). (A)
Left panels. Representative confocal images of BHK cells
transfected with GFP-MARCKS under basal conditions (‘‘no
treatment’’) or 20 s after application of the PKC activator 12-O-
tetradecanoylphorbol-13-acetate (‘‘TPA,’’ 0.1 mM). Right panels.
Similar experiments were carried out in the presence of 10 mM
AMPA Receptors and Enhanced Cognition
PLoS Biology | www.plosbiology.org 15 February 2012 | Volume 10 | Issue 2 | e1001262chelerythrine. (B) Quantification of GFP-MARCKS fluorescence
intensity ratios between the cell plasma membrane and the cytosol
from two independent experiments as the one shown in (A). N
represents number of cells. (C) Western blot of hippocampal
extracts from slices treated for 30 min with TPA (0.5 mM),
chelerythrine (10 mM), or a combination of both, as indicated.
Control slices were treated with vehicle (0.1% DMSO). Phos-
phorylation of MARCKS at the PKC specific sites Ser152/156,
total levels of MARCKS, and tubulin (as loading control) were
monitored with specific antibodies. (D) Quantification of phos-
phorylated to total ratios of MARCKS from four independent
experiments as the one shown in (C).
(TIF)
Figure S4 FGL facilitates LTP in CA1 neurons. Cumulative
frequency distribution of EPSC fold potentiation from the
individual LTP experiments plotted in Figure 6D–E. Data are
presented for control slices or slices treated with FGL, cheler-
ythrine, or FGL plus chelerythrine, as indicated.
(TIF)
Figure S5 FGL does not alter long-term synaptic depression.
Organotypic slice cultures were treated with FGL for 24 h and
then transferred to fresh culture medium (without FGL) for an
additional 24 h prior to recordings. Control slices were kept in
regular culture medium until the recordings. LTD was induced by
pairing presynaptic 1 Hz stimulation (300 pulses) with moderate
postsynaptic depolarization (240 mV) (black bar). Inset: sample
traces of evoked AMPAR-mediated synaptic responses before (thin
line) and after (thick line) LTD induction. N, number of cells.
(TIF)
Figure S6 FGL alters NMDAR decay kinetics in a PKC-
independent manner. Organotypic slice cultures were treated with
FGL (with or without chelerythrine) for 24 h and then transferred
to fresh culture medium for an additional 24 h prior to recordings.
Control slices were kept in regular culture medium until the
recordings. NMDAR-mediated synaptic responses were recorded
at +40 mV in the presence of CNQX (AMPAR antagonist). (A)
Average trace of NMDAR response normalized to its peak
amplitude from untreated (blue), FGL-treated (grey), or FGL plus
chelerythrine-treated slices (red). Standard error of the mean is
plotted for each trace as thin dashed lines. (B) Average half-decay
time (T1/2) of NMDA responses from the same data plotted in (A).
FGL treatment produces a significant reduction in the half-decay
time, which is not blocked by PKC inhibition (chelerythrine).
(TIF)
Figure S7 FGL does not alter structural plasticity of dendritic
spines. (A) Representative confocal fluorescence image of dendritic
spines expressing actin-GFP before (09) or at different times after
induction of LTP (59,2 0 9) from untreated or FGL-treated
organotypic slices. Spine heads undergoing plasticity are marked
with arrows. LTP was induced using a standard pharmacological
protocol (see Text S1). (B) Time-course of actin-GFP fluorescence
at individual spine heads before, during (grey shade), and after
LTP induction, from images as the one shown in (A). Fluorescence
values in the spine head were normalized to the average value in
the dendritic shaft (to compensate for ongoing fluorescence
bleaching) and expressed relative to the baseline. Analysis was
done blind with respect to the treatment the slices had received.
(TIF)
Figure S8 PKC inhibition does not alter spatial learning. Mean
distances swam to find the hidden platform in the Morris water
maze from vehicle- (white column) and PKC inhibitor-treated rats
(gray columns; A, chelerythrine; B, GF109203X), over the eight
training trials (four trials per day). N, the number of animals.
(TIF)
Figure S9 Spatial learning in the Morris water maze is altered
by MEK and PI3K inhibitors. Mean distances traveled to find the
hidden platform in the Morris water maze over the 2 training days
(four trials each). N, number of animals. Rats injected with vehicle,
FGL (20 mg), PD98059 (MEK inhibitor, 20 nmol), or LY294002
(PI3K inhibitor, 4.5 nmol), as indicated.
(TIF)
Text S1 Additional experimental procedures are described in
this supplementary text.
(DOCX)
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